1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 8th April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

[Preprint] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge (2022) Killingley et al

Discussion in 'Epidemics (including Covid-19, not Long Covid)' started by Milo, Feb 5, 2022.

Tags:
  1. Milo

    Milo Senior Member (Voting Rights)

    Messages:
    2,108
    This is the paper linked to the experiment of inoculating young adults with COVID early in 2020.

    Abstract:

    To establish a novel SARS-CoV-2 human challenge model, 36 volunteers aged 18-29 years without evidence of previous infection or vaccination were inoculated with 10 TCID50 of a wild-type virus (SARS-CoV-2/human/GBR/484861/2020) intranasally.

    Two participants were excluded from per protocol analysis due to seroconversion between screening and inoculation. Eighteen (~53%) became infected, with viral load (VL) rising steeply and peaking at ~5 days post-inoculation.

    Virus was first detected in the throat but rose to significantly higher levels in the nose, peaking at ~8.87 log10 copies/ml (median, 95% CI [8.41,9.53).

    Viable virus was recoverable from the nose up to ~10 days post-inoculation, on average. There were no serious adverse events.

    Mild-to-moderate symptoms were reported by 16 (89%) infected individuals, beginning 2-4 days post-inoculation.

    Anosmia/dysosmia developed more gradually in 12 (67%) participants.

    No quantitative correlation was noted between VL and symptoms, with high VLs even in asymptomatic infection, followed by the development of serum spike-specific and neutralising antibodies.

    However, lateral flow results were strongly associated with viable virus and modelling showed that twice-weekly rapid tests could diagnose infection before 70-80% of viable virus had been generated.

    Thus, in this first SARS-CoV-2 human challenge study, no serious safety signals were detected and the detailed characteristics of early infection and their public health implications were shown. ClinicalTrials.gov identifier: NCT04865237

    Link to paper here
    Link to the related Science article here
     
    Peter Trewhitt and Andy like this.
  2. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    12,421
    Location:
    Canada
    That's weird. Or maybe just the result of rigorous record-keeping. It wouldn't be much of a surprise if most "asymptomatic" cases are actually mild symptoms that people simply shrug off, or simply don't mention. Otherwise this is much higher than usually reported.
     

Share This Page